Baiyunshan (00874) Multiple products were selected and withdrawn from the “National Catalogue of Basic Drugs”

Zhitong Finance App News, Baiyunshan (00874) announced that recently, the National Health Commission, the State Administration of Traditional Chinese Medicine, and the National Administration of Disease Prevention and Control released the “National Essential Drug Catalogue (2026 Edition)”. According to statistics, the company's branches Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan He Jigong Pharmaceutical Factory and its subsidiaries Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. and Guangzhou Wanglaoji Pharmaceutical Co., Ltd. are involved in the entry or exit of new products from the “National Pharmaceutical Catalogue”.

New entry or exit situations

Among the products newly added to the “National Essential Medicines Catalogue”, Xiaochaihu granules are the company's main product. This product is included in the “National Medical Insurance Catalogue” (2025 edition). It has the effects of relieving fever, relieving liver and stomach, treating external diseases. The symptoms are cold and heat, chest tension, loss of appetite, upset, and dry mouth. In 2025, Guanghua Pharmaceutical and Wang Laoji Pharmaceutical had revenue of RMB 46,70597 million and RMB 30.401 million respectively, which together accounted for 0.64% of the company's revenue in 2025. The revenue of other newly introduced and released products in the “National Basic Drug Catalogue” in 2025 accounted for a small proportion of the company's revenue.

The new entry of the company's products into the “National Basic Drug Catalogue” will facilitate market expansion and sales of related products. It is not expected to have a significant impact on the company's business performance in the short term, but it will help expand the market and increase the sales scale of these products in the long term. Sales revenue from the company's withdrawal from the “National Basic Drug Catalogue” products accounts for a small proportion of the company's revenue, and its withdrawal will not have a significant impact on the company's business performance. Pharmaceutical production and sales are easily affected by factors such as national policies and the market environment, and there is great uncertainty. Investors are kindly requested to make careful decisions and pay attention to preventing investment risks.